Novaliq GmbH
https://www.novaliq.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novaliq GmbH
New Drugs For Gastric Cancer, Liver Disease Among 14 Products Heading For EU Approval
Two orphan drugs are among a host of products that the European Medicines Agency’s human medicines committee has OKd for pan-EU approval.
EU Moment Of Truth For Lecanemab & 14 Other Drugs
Eisai/Biogen could this week learn whether the European Medicines Agency will give the thumbs up to market lecanemab across the EU for early Alzheimer’s disease.
Pharma Looks To America First: US FDA Holds Overwhelming Lead Over EMA In Novel Approvals
A Pink Sheet analysis finds US approval preceded European Union clearance for 80% of products approved in both areas, but when EU approval came first, it beat the FDA by a median of 13 months. US-first approvals came close to six months before the EU.
OKYO Hits Multiple Dry Eye Endpoints, Plans Move Into Phase III
OKYO’s eye drop OK-101 has hit endpoints for ocular pain, tear film breakup time and conjunctival staining in Phase II, while demonstrating a placebo-like tolerability profile.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
- Other Names / Subsidiaries
-
- Novaliq Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice